# Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

> **NCT02499770** · PHASE1,PHASE2 · COMPLETED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Placebo
- **DRUG:** Trilaciclib
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT02499770
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-26
- **Primary completion:** 2017-07-03
- **Final completion:** 2019-02-22
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499770, "Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02499770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*